Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

A fourth tab, called “DEXA cohort 9 four,” contains patient-level data for the top MariTide dose. Cantor analyst Olivia ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Gilead Sciences (GILD – Research Report) yesterday and set a price ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a ...

Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...

Operator: Your next question comes from the line of Olivia Brayer from Cantor Fitzgerald. Olivia Brayer: You guys have shown some really nice potency data for AUR200. So how are you thinking about ...

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone marrow density data for Amgen’s obesity candidate MariTide ...

Operator: Your next question comes from the line of Olivia Brayer from Cantor Fitzgerald. Olivia Brayer: You guys have shown some really nice potency data for AUR200. So how are you thinking about ...

For now, we're pleased with the number of patients we have and the success of the registry. Operator: Your next question comes from the line of Olivia Brayer from Cantor Fitzgerald. Olivia Brayer: You ...